Log In
BCIQ
Print this Print this
 

biosimilar infliximab (ABP 710)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBiosimilar infliximab, humanized mAb against tumor necrosis factor (TNF) alpha.
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today